Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Diagnostic & Testing Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:OXFD
- CUSIP: N/A
- Web: www.oxfordimmunotec.com
Capitalization:- Market Cap: $399.91 million
- Outstanding Shares: 23,076,000
Average Prices:- 50 Day Moving Avg: $16.84
- 200 Day Moving Avg: $15.20
- 52 Week Range: $9.38 - $19.51
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.30
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $97.44 million
- Price / Sales: 3.79
- Book Value: $2.28 per share
- Price / Book: 7.03
Profitability:- EBIDTA: ($23,660,000.00)
- Net Margins: -34.58%
- Return on Equity: -35.76%
- Return on Assets: -21.67%
Debt:- Debt-to-Equity Ratio: 0.57%
- Current Ratio: 2.93%
- Quick Ratio: 2.51%
Misc:- Average Volume: 84,020 shs.
- Beta: -0.11
- Short Ratio: 6.65
Frequently Asked Questions for Oxford Immunotec Global PLC (NASDAQ:OXFD)
What is Oxford Immunotec Global PLC's stock symbol?
Oxford Immunotec Global PLC trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global PLC's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) released its earnings results on Tuesday, August, 1st. The company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.32). The firm had revenue of $26.10 million for the quarter, compared to analysts' expectations of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The business's quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS. View Oxford Immunotec Global PLC's Earnings History.
When will Oxford Immunotec Global PLC make its next earnings announcement?
Where is Oxford Immunotec Global PLC's stock going? Where will Oxford Immunotec Global PLC's stock price be in 2017?
3 equities research analysts have issued 12-month price targets for Oxford Immunotec Global PLC's stock. Their predictions range from $19.00 to $26.00. On average, they expect Oxford Immunotec Global PLC's share price to reach $22.33 in the next twelve months. View Analyst Ratings for Oxford Immunotec Global PLC.
What are analysts saying about Oxford Immunotec Global PLC stock?
Here are some recent quotes from research analysts about Oxford Immunotec Global PLC stock:
- 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (8/5/2017)
- 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)
Who are some of Oxford Immunotec Global PLC's key competitors?
Some companies that are related to Oxford Immunotec Global PLC include CRISPR THERAPTC (CRSP), TG Therapeutics (TGTX), Keryx Biopharmaceuticals (KERX), Cellectis S.A. (CLLS), Insmed (INSM), ZIOPHARM Oncology (ZIOP), Epizyme (EPZM), U.S. Physical Therapy (USPH), Anika Therapeutics (ANIK), Enanta Pharmaceuticals (ENTA), NeoGenomics (NEO), Flexion Therapeutics (FLXN), Revance Therapeutics (RVNC), Vanda Pharmaceuticals (VNDA), Aclaris Therapeutics (ACRS), Heska Corporation (HSKA), La Jolla Pharmaceutical Company (LJPC) and Akebia Therapeutics (AKBA).
Who are Oxford Immunotec Global PLC's key executives?
Oxford Immunotec Global PLC's management team includes the folowing people:
- Richard A. Sandberg, Independent Chairman of the Board
- Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director
- Richard M. Altieri, Chief Financial Officer
- Peter Edwardson Ph.D., Chief Operating Officer
- Stephen M. Gansler, Senior Vice President and Global Head of Human Resources
- Elizabeth M. Keiley, Vice President, General Counsel
- Jeff R. Schroeder, Chief Commercial Officer
- Richard Wenstrup M.D., Chief Medical Officer
- .. Scott .., Director
- Ronald A. Andrews Jr., Director
Who owns Oxford Immunotec Global PLC stock?
Oxford Immunotec Global PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (9.34%), AXA (3.88%), Grandeur Peak Global Advisors LLC (3.05%), First Light Asset Management LLC (2.27%), State Street Corp (1.94%) and Northern Trust Corp (1.06%). Company insiders that own Oxford Immunotec Global PLC stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global PLC.
Who sold Oxford Immunotec Global PLC stock? Who is selling Oxford Immunotec Global PLC stock?
Oxford Immunotec Global PLC's stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, First Light Asset Management LLC, Tiverton Asset Management LLC, Wells Fargo & Company MN, Neuberger Berman Group LLC, AXA, Flinton Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Oxford Immunotec Global PLC stock in the last year include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global PLC.
Who bought Oxford Immunotec Global PLC stock? Who is buying Oxford Immunotec Global PLC stock?
Oxford Immunotec Global PLC's stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Penn Capital Management Co. Inc., State Street Corp, Northern Trust Corp, Essex Investment Management Co. LLC, Asymmetry Capital Management L.P., Alliancebernstein L.P. and Teachers Advisors LLC. View Insider Buying and Selling for Oxford Immunotec Global PLC.
How do I buy Oxford Immunotec Global PLC stock?
Shares of Oxford Immunotec Global PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global PLC's stock price today?
One share of Oxford Immunotec Global PLC stock can currently be purchased for approximately $16.02.
MarketBeat Community Rating for Oxford Immunotec Global PLC (NASDAQ OXFD)MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Oxford Immunotec Global PLC (NASDAQ:OXFD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $22.33 (39.41% upside) |
Analysts' Ratings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/3/2017 | Cowen and Company | Reiterated Rating | Buy | $22.00 | Low |  |
| 8/3/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $26.00 | Low | |
| 5/4/2017 | BTIG Research | Reiterated Rating | Buy | | Medium | |
(Data available from 8/16/2015 forward)
Earnings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Earnings History by Quarter for Oxford Immunotec Global PLC (NASDAQ OXFD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | ($0.17) | | | | | N/A | |
| 8/1/2017 | Q2 2017 | ($0.32) | ($0.32) | $25.05 million | $26.10 million | View | Listen | |
| 5/2/2017 | 3/31/2017 | ($0.35) | ($0.36) | $21.17 million | $21.51 million | View | Listen | |
| 3/1/2017 | 12/31/2016 | ($0.39) | ($0.22) | $23.06 million | $23.71 million | View | Listen | |
| 11/1/2016 | Q316 | ($0.33) | ($0.18) | $24.79 million | $26.10 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.33) | ($0.29) | $18.10 million | $19.20 million | View | N/A | |
| 5/3/2016 | Q116 | ($0.32) | ($0.32) | $16.96 million | $17.10 million | View | N/A | |
| 3/1/2016 | Q415 | ($0.28) | ($0.29) | $16.34 million | $16.00 million | View | N/A | |
| 11/3/2015 | Q315 | ($0.25) | ($0.20) | $17.31 million | $17.90 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.34) | ($0.33) | $14.04 million | $14.30 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.33) | ($0.31) | $13.35 million | $13.80 million | View | N/A | |
| 3/3/2015 | Q414 | ($0.44) | ($0.39) | $11.93 million | $12.10 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.38) | ($0.35) | $12.85 million | $13.30 million | View | N/A | |
| 8/5/2014 | Q214 | ($0.20) | ($0.36) | $11.39 million | $11.80 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.18) | ($0.18) | $11.64 million | $12.30 million | View | N/A | |
| 3/4/2014 | Q413 | ($0.19) | ($0.38) | $9.28 million | $10.20 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Oxford Immunotec Global PLC (NASDAQ:OXFD)Current Year EPS Consensus Estimate: $-1.56 EPS
Next Year EPS Consensus Estimate: $-0.83 EPS
Dividend History for Oxford Immunotec Global PLC (NASDAQ:OXFD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Insider Ownership Percentage: 7.58%
Institutional Ownership Percentage: 84.96%
Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/7/2017 | Peter Edwardson | COO | Sell | 22,371 | $17.70 | $395,966.70 | |
| 7/6/2017 | Peter Wrighton-Smith | CEO | Sell | 27,168 | $15.94 | $433,057.92 | |
| 7/5/2017 | Peter Wrighton-Smith | CEO | Sell | 32,832 | $16.58 | $544,354.56 | |
| 6/28/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $16.06 | $481,800.00 | |
| 6/15/2017 | Elizabeth M Keiley | VP | Sell | 4,085 | $15.01 | $61,315.85 | |
| 5/15/2017 | Peter Edwardson | COO | Sell | 10,000 | $14.66 | $146,600.00 | |
| 5/10/2017 | Richard A Sandberg | Director | Sell | 3,000 | $14.40 | $43,200.00 | |
| 5/9/2017 | Jeff R Schroeder | Insider | Sell | 40,000 | $14.14 | $565,600.00 | |
| 4/3/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $15.43 | $462,900.00 | |
| 4/3/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.47 | $46,410.00 | |
| 3/20/2017 | Elizabeth M Keiley | VP | Sell | 3,000 | $16.05 | $48,150.00 | |
| 2/6/2017 | Peter Wrighton-Smith | CEO | Sell | 25,000 | $13.36 | $334,000.00 | |
| 12/16/2016 | Peter Wrighton-Smith | CEO | Sell | 7,052 | $15.07 | $106,273.64 | |
| 12/5/2016 | Peter Wrighton-Smith | CEO | Sell | 1,140 | $15.00 | $17,100.00 | |
| 12/2/2016 | Peter Wrighton-Smith | CEO | Sell | 61,808 | $15.00 | $927,120.00 | |
| 11/8/2016 | Richard A Sandberg | Director | Sell | 12,000 | $14.17 | $170,040.00 | |
| 11/18/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.48 | $67,400.00 | |
| 11/17/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.00 | $65,000.00 | |
| 6/16/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 41,230 | $14.30 | $589,589.00 | |
| 6/15/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 1,529 | $14.27 | $21,818.83 | |
| 6/12/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 31,598 | $14.27 | $450,903.46 | |
| 6/10/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 24,649 | $14.28 | $351,987.72 | |
| 6/9/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 13,000 | $14.26 | $185,380.00 | |
| 6/8/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 2,662 | $14.25 | $37,933.50 | |
| 6/3/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 36,474 | $14.29 | $521,213.46 | |
| 6/1/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.14 | $42,420.00 | |
| 3/23/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 53,415 | $14.49 | $773,983.35 | |
| 3/19/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 154,319 | $14.65 | $2,260,773.35 | |
| 1/14/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.00 | $42,000.00 | |
| 12/5/2014 | Patricia Randall | Director | Sell | 5,000 | $12.06 | $60,300.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Latest Headlines for Oxford Immunotec Global PLC (NASDAQ:OXFD)
| Source: |
|
| Date | Headline |
|---|
 | Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - August 16 at 6:34 AM |
 | Oxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM |
| Oxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM |
| Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM |
| Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM |
 | Alphatec Holdings (ATEC) & Oxford Immunotec Global PLC (OXFD) Critical Comparison
www.americanbankingnews.com - August 14 at 4:22 AM |
| Zacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.17 Million
www.americanbankingnews.com - August 11 at 10:02 AM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - August 10 at 12:28 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) COO Peter Edwardson Sells 22,371 Shares
www.americanbankingnews.com - August 9 at 8:44 PM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 6 at 8:56 AM |
| HTG Molecular Diagnostics (HTGM) versus Oxford Immunotec Global PLC (NASDAQ:OXFD) Head-To-Head Review
www.americanbankingnews.com - August 3 at 2:26 PM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 3 at 12:38 PM |
| Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017
finance.yahoo.com - August 3 at 6:43 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 2 at 10:32 AM |
| Oxford Immunotec Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:44 AM |
| Edited Transcript of OXFD earnings conference call or presentation 1-Aug-17 12:00pm GMT
finance.yahoo.com - August 2 at 6:44 AM |
| Oxford Immunotec reports 2Q loss
finance.yahoo.com - August 2 at 6:44 AM |
| Oxford Immunotec Global PLC (NASDAQ:OXFD) Issues Earnings Results
www.americanbankingnews.com - August 1 at 2:20 PM |
| Reviewing Cepheid (CPHD) and Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - July 27 at 4:25 PM |
| Oxford Immunotec Global PLC (OXFD) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 27 at 2:39 PM |
| Oxford Immunotec (OXFD) Appoints Richard Wenstrup as CMO
www.streetinsider.com - July 25 at 5:41 AM |
| Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer
finance.yahoo.com - July 24 at 2:35 PM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.30 Million
www.americanbankingnews.com - July 22 at 8:50 AM |
| -$0.32 EPS Expected for Oxford Immunotec Global PLC (NASDAQ:OXFD) This Quarter
www.americanbankingnews.com - July 20 at 6:24 PM |
| Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017
finance.yahoo.com - July 19 at 1:31 AM |
| Comparing WaferGen Bio-systems (WGBS) & Oxford Immunotec Global PLC (NASDAQ:OXFD)
www.americanbankingnews.com - July 16 at 10:28 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $433,057.92 in Stock
www.americanbankingnews.com - July 10 at 8:13 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $544,354.56 in Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Analyzing HTG Molecular Diagnostics (HTGM) & Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - July 6 at 12:32 AM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $481,800.00 in Stock
www.americanbankingnews.com - June 29 at 7:48 PM |
| $25.33 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - June 28 at 10:52 AM |
| Oxford Immunotec Global PLC (OXFD) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - June 26 at 4:12 PM |
 | Oxford Immunotec: Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
www.finanznachrichten.de - June 23 at 8:52 AM |
| Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
finance.yahoo.com - June 23 at 8:52 AM |
| Contrasting Oxford Immunotec Global PLC (OXFD) & Myriad Genetics (MYGN)
www.americanbankingnews.com - June 23 at 8:16 AM |
| Oxford Immunotec Global PLC (OXFD) VP Elizabeth M. Keiley Sells 4,085 Shares
www.americanbankingnews.com - June 16 at 7:58 PM |
| Zacks: Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - June 16 at 10:30 AM |
| ETFs with exposure to Oxford Immunotec Global Plc : June 15, 2017
finance.yahoo.com - June 16 at 8:36 AM |
| Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
finance.yahoo.com - June 16 at 8:36 AM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bullish Manner : OXFD-US : June 16, 2017
finance.yahoo.com - June 16 at 8:36 AM |
| Analyzing SurModics (SRDX) and Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - June 11 at 8:26 AM |
| Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : June 6, 2017
finance.yahoo.com - June 6 at 7:55 PM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bullish Manner : OXFD-US : June 5, 2017
finance.yahoo.com - June 5 at 7:44 PM |
 | Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations
feeds.benzinga.com - June 5 at 8:22 AM |
| Oxford Immunotec Global PLC (OXFD) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 3 at 6:58 PM |
| Oxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $25.33 Million
www.americanbankingnews.com - June 2 at 1:48 PM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 31 at 12:48 PM |
| ETFs with exposure to Oxford Immunotec Global Plc : May 26, 2017
finance.yahoo.com - May 26 at 8:16 PM |
| Peter Edwardson Sells 10,000 Shares of Oxford Immunotec Global PLC (OXFD) Stock
www.americanbankingnews.com - May 16 at 7:53 PM |
| Insider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - May 11 at 8:48 PM |
Oxford Immunotec Global PLC (OXFD) Chart for Wednesday, August, 16, 2017
